Proof, published August 2025
Precision KOL Identification for Rare Disease Market Entry: A Strategic Roadmap Case Study
Executive summary
A rare disease pharmaceutical company needed to optimize its Ontario sales territory coverage for an extremely niche pediatric therapeutic. We delivered a ranked list of 71 specialists with 33 high-priority targets, plus a replicable blueprint for market expansion.
The challenge
The situation
- A single sales rep covering all of Ontario
- An extremely niche rare disease product in a pediatric population
- Prescribing spread across multiple specialties created targeting confusion
- The company was planning expansion but lacked a systematic approach for new territories
The complexity: multiple specialist types could potentially prescribe, including pediatricians, pediatric endocrinologists, pediatric neurologists, neurologists and ENT specialists. That made it hard to separate true expertise from occasional prescribing.
Our solution
Research method
- Systematic analysis of medical journals and publications
- Institutional expertise mapping and treatment centre evaluation
- Individual specialist background verification and clinical experience assessment
- Cross-referencing across multiple data sources for validation
Key deliverables
- Ranked KOL database: 71 specialists identified, with 33 high-priority targets (score 7+/10)
- Replicable blueprint: a step-by-step method for KOL identification in new territories
- Strategic framework: a training guide for onboarding future sales reps
Results and impact
I think the blueprint is insightful and on point with the messaging. Most importantly, the list of potential KOLs: some of these specialists are already on my list to contact, and others I wasn’t aware of, which is great.
Client, rare disease pharma company
Value delivered
- Precision: 46% of identified specialists qualified as high-priority targets
- Expansion: a replicable framework for setting up new territories
- Resource use: clear prioritization for time and travel
- Quality: the medical affairs team endorsed the method as "very, very well done"
Conclusion
This project moved territory coverage from broad-based to precision-targeted, and left the company with a method it can reuse in new territories.
Entering a rare disease market?
Book 30 minutes and we’ll talk through KOL identification and a blueprint for your indication.